MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference
January 05 2022 - 6:10AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer Michael
Castagna, PharmD, will present at the H.C. Wainwright Bioconnect
Conference which will be available on demand starting on January
10, 2022.
Interested parties can access a link to the on
demand webcast of the presentation from the Events &
Presentations section of the Company’s website at
https://investors.mannkindcorp.com/events-and-presentations. The
webcast replay may be accessed at the same location for 14
days.
About MannKind CorporationMannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
inhaled therapeutic products for patients with endocrine and orphan
lung diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin in
the United States, where it is available by prescription from
pharmacies nationwide. Afrezza is also available by prescription in
Brazil, where it is commercialized by the Company’s partner, Biomm
SA. MannKind was established in 1991, and is located in Danbury,
Conn., and Westlake Village, Calif. The Company also employs field
sales and medical representatives across the U.S. Please visit
mannkindcorp.com to learn more.
Contact:Rose Alinaya, Investor Relations (818) 661-5000 Email:
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024